Analysis of Preimplantation Genetic Testing market covering 30 + countries including analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
The preimplantation genetic testing market is projected to grow at nearly 9% CAGR and is likely to register an impressive valuation through 2032. The increasing prevalence of genetic disorders is broadening growth prospects.
As of 2022, the market is likely to reach US$ 653.52 Million, and will further accelerate to reach US$ 1,420 Million by 2032.
Preimplantation Genetic Testing Market Size (2022)
US$ 653.52 Million
Projected Market Value (2032F)
US$ 1,420 Million
Global Market Growth Rate (2022-2032)
Asia Pacific Market Share (2022)
North America Market Share (2022)
Key Companies Profiled
The Asia Pacific contributes a major share of the global market due to rapid advancements in the healthcare industry developments in countries such as India, China, Indonesia, and Vietnam.
The increasing acceptance of embryo HLA typing for stem cell therapy and improving healthcare infrastructure sector in the region is also expected to boost demand for Preimplantation Genetic Testing to US$ 1,420 Mn by 2032.
Don't Need a Global Report?
Save 40% on Country & Region specific reports
As per Fact.MR –market research and competitive intelligence provider- over the last 5 years, the global market for preimplantation genetic testing expanded at an 8% CAGR. In 2020, the market was valued at around US$ 550 Million.
Preimplantation genetic testing is gaining traction for diagnosing minor disabilities and other serious diseases such as cancer. Researchers are also focusing on using innovative techniques for eliminating the possibility of embryo destruction while preimplantation genetic testing.
All these factors create an ideal environment for preimplantation genetic testing across the world, and the market is expected to show an impressive valuation by 2032, expanding at nearly 9% CAGR.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Increasing Prevalence of Genetic Screening across Specialized Clinics to Fuel Global Demand
Genetic screening is expected to be the most preferred preimplantation genetic testing approach. The section is projected to gain a nearly 2/3rd share of the market for preimplantation genetic testing in terms of revenue until 2032.
According to the Centers for Disease Control and Prevention (CDC), chronic ailments such as cancer, heart disorders, and diabetes are the leading cause of disability and death in people across the United States.
The country’s healthcare system spends nearly US$ 3 Billion annually on direct and indirect costs. In addition to this, the increasing awareness regarding the effectiveness of genetic testing methods amongst healthcare professionals is projected to favor market growth in forthcoming years.
Amongst all end users, specialized clinics are expected to experience strong growth. They are estimated to exceed the US$ 200 Million revenue threshold during the forecast period. Meanwhile, hospitals are also expected to witness impressive growth in the global market for preimplantation genetic testing through 2032.
In June 2020, The U.S. Food and Drug Administration issued an emergency use authorization (EUA) to Illumina, Inc. for the first COVID-19 diagnostic test utilizing next-generation sequence technology. The FDA authorized the Illumina COVIDSeq Test for the qualitative detection of SARS-CoV-2 RNA from respiratory specimens collected from individuals suspected of COVID-19 by their healthcare provider.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Higher Cost of Testing May Impede the Market Growth
Despite several benefits, this genetic testing comes along with a few restraints that impact the market growth. High costs associated with preimplantation genetic testing and unfavorable government regulations are the perennial challenges to market growth. In Addition, a dearth of awareness in poor countries may restrain the growth of preimplantation genetic testing.
Rapid Advancement by New Entrants to Elevate Demand for Preimplantation Genetic Testing
Witnessing the immense growth in the genome treatment sector, emerging startups are making efforts to provide effective testing services to the clinician for pre-implantation genetic diagnosis (PGD), mutation screening, and prenatal testing. These efforts are likely to amplify the global acceptance of genetic testing for its application in several fields.
For instance, In June 2022, Natera, Inc., a global leader in cell-free DNA testing, announced at the Canaccord Genuity 42nd Annual Growth Conference in Boston that the company has proactively filed a pre-submission to the FDA for its Panorama® non-invasive prenatal test (NIPT) as part of the Q-Sub process. The company filed its pre-submission for fetal chromosomal aneuploidies and 22q11.2 deletion syndrome.
Along with this, another key start-up, Progenity is offering an option of non-invasive testing. The company's diagnostic platform is based on genomics, epigenomics, proteomics, and metabolomics.
North America Offers the Largest Opportunity for Preimplantation Genetic Testing Providers
In 2021, North America surpassed Europe as the leading region in the Preimplantation Genetics Diagnosis (PGD) market, accounting for the highest sales. This growth is attributed to an increase in the country's population and money spent on healthcare.
As of 2021, 489 fertility clinics in the United States offer ART solutions, as per the report published by the US Department of Health and Human Services. The states with the maximum proportion of ART births are Massachusetts, Columbia, and New Jersey. In addition, a growing number of chromosome abnormality cases in the region leads to various genetic disorders. A CAGR of 7% has been projected for the market.
According to CDC, each year, about 6,000 babies are born with Down syndrome, which is about 1 in every 700 babies born. Down syndrome among newborn babies in the U.S continues to be the most common chromosomal disorder, broadening the scope of preimplantation genetic testing across the North American region.
Increasing Prevalence of Genetic Disorders to Bolster Demand for these Testing
The UK is projected to be the most lucrative market for preimplantation genetic testing across Europe. Fact.MR estimates a CAGR of around 8% for the U.K market across the forecast period. In 2021, the market demand is projected to bolster, owing to the presence of various healthcare institutions and hospitals providing preimplantation genetic testing and high awareness due to the various initiatives by the government.
Moreover, genetic testing in the U.K increasing as the country amid a high incidence of genetic disorders. According to Genetic Alliance, it is estimated that at least 1 child out of 25 is affected by a genetic disorder. This means that 30,000 babies are diagnosed each year and more than 500 million children and adults are living with a genetic disorder. Owing to these factors, the market is projected to expand through 2032.
China Presents Robust Opportunities
Emerging economies such as China and India are experiencing numerous advancements in their respective healthcare sectors. Reproductive health is especially accompanied by the launch of several supportive governmental legislations. Collectively, both regions are expected to contribute nearly 60% of total revenue.
The presence of regulatory bodies, such as the Indian Ministry of Health & Family Welfare, which approve and monitor the challenges associated with reproductive health in India: is anticipated to bode well for regional growth of the market for preimplantation genetic testing.
Embryo HLA typing Applications to Garner two-fifth Market Share
Preimplantation genetic testing is likely to find maximum application in embryo HLA typing for stem cell therapy. Accounting for more than 40% of revenue, embryo HLA typing for stem cell therapy is projected to generate an incremental opportunity exceeding US$ 70 Million by 2032.
Soaring Investments in NGS to Accelerate Market Growth
Next-generation sequencing (NGS) is expected to be the dominant preimplantation genetic testing technology. NGS is estimated to exceed US$ 200 Million in revenue during the forecast period.
According to the Centers for Disease Control and Prevention during the past 5 years, NGS has transitioned from research to clinical use. At least 14 countries have created initiatives to sequence large populations, and it is projected that more than 60 million people worldwide will have their genomes sequenced by 2025.
- Premium Report Details -
- Let's Connect -
- Quick Contact -
- Get Started -
Get insights that lead to new growth opportunitiesBuy Now
Get A Special pricing for start-ups and universitiesEnquiry Before Buying
- Humble, Yet Honored -
- Research Methodology -
An Adaptive Approach to Modern-day Research NeedsGet Methodology
- Related Reports -
By Application type, Testing for embryo HLA typing for stem cell therapy is likely to generate incremental opportunity exceeding US$ 70 Mn by 2032.
As of 2022, Fact.MR expects the Preimplantation Genetic Testing industry to be valued at US$ 653.52 Million.
From 2022 to 2032, the Preimplantation Genetic Testing industry is poised to flourish at a 9% CAGR.
By 2032, the Preimplantation Genetic Testing landscape is slated to reach a valuation of US$ 1420 Million.
According to Fact.MR, a CAGR of 8% was recorded for the Preimplantation Genetic Testing market from 2017-2021.
As per Fact.MR’s projections, the market for Preimplantation Genetic Testing in Europe will likely expand at a 60% CAGR.
As of 2021, the Preimplantation Genetic Testing market was valued at US$ 599.53 Million.
Need An Exclusive Report For Your Unique Requirement?